证券代码：301087 证券简称：可孚医疗 公告编号：2025-018 可孚医疗科技股份有限公司 第二届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届监事会第十四次会 议于 2025 年 4 月 15 日以电子邮件的方式发出会议通知，会议于 2025 年 4 月 25 日上午 11:00 在公司六楼会议室以现场会议方式召开。会议应出席监事 3 名，实 际出席监事 3 人。本次会议由监事会主席曾子云先生主持，董事会秘书列席会议。 会议的召集和召开符合《中华人民共和国公司法》等法律法规和《公司章程》的 有关规定。 二、监事会会议审议情况 与会监事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1. 审议通过了《关于公司<2024 年年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2024 年年度报告的程序符合 相关法律法规以及中国证监会、深圳证券交易所的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-017 可孚医疗科技股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会第十四次会 议于 2025 年 4 月 15 日以电子邮件的方式发出会议通知，会议于 2025 年 4 月 25 日上午 9:30 在公司六楼会议室以现场会议方式召开。会议应出席董事 7 名，实 际出席董事 7 人，公司监事、高级管理人员列席了会议。本次会议由董事长张敏 先生主持。会议的召集和召开符合《中华人民共和国公司法》等法律法规和《公 司章程》的有关规定。 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1. 审议通过了《关于公司<2024 年年度报告>及其摘要的议案》 公司 2024 年年度报告全文及其摘要遵循相关法律法规及规范性文件要求编 制，报告内容真实、准确、完整地反映了公司 2024 年度的经营情况，不存在任 何虚假记载、误导性陈述或者重大遗漏。 具体 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,982,931,130.48, representing a 4.53% increase compared to ¥2,853,694,939.62 in 2023 [19]. - Net profit attributable to shareholders for 2024 was ¥311,750,944.39, a 22.60% increase from ¥254,279,785.84 in 2023 [19]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥275,062,929.19, up 36.74% from ¥201,151,337.34 in 2023 [19]. - The net cash flow from operating activities for 2024 was ¥663,393,280.10, a significant increase of 68.45% compared to ¥393,822,676.57 in 2023 [19]. - Basic earnings per share for 2024 were ¥1.53, reflecting a 23.39% increase from ¥1.24 in 2023 [19]. - Total assets at the end of 2024 amounted to ¥6,422,666,712.07, a 2.86% increase from ¥6,244,191,736.83 at the end of 2023 [19]. - The company reported a weighted average return on equity of 6.41% for 2024, an increase of 1.20 percentage points from 5.21% in 2023 [19]. - The company achieved operating revenue of 2.983 billion yuan, a year-on-year increase of 4.53%, and a net profit attributable to shareholders of 312 million yuan, up 22.60% [56]. - The company’s cash flow from operating activities reached 663 million yuan, reflecting a significant year-on-year growth of 68.45% [56]. Dividend Distribution - The company plans to distribute a cash dividend of 12 RMB per 10 shares to all shareholders, based on a total of 203,392,269 shares eligible for distribution [3]. - The total cash dividend for 2024 is projected to be 366,107,764.20 CNY, which includes 122,037,041.40 CNY for the first half of 2024 [180]. - The cash dividend distribution for 2023 will be executed on June 2024, while the 2024 semi-annual distribution is set for October 2024 [179]. - The total cash dividend amount, including other methods, accounts for 100% of the distributable profit [177]. - The company has maintained a consistent cash dividend policy without any adjustments during the reporting period [176]. Market and Industry Trends - The medical device industry is entering a high-quality development phase, supported by national policies and an aging population [26]. - The domestic medical device market is expected to reach ¥1.35 trillion in revenue for 2024, with growth driven by aging population and health awareness [28]. - By the end of 2024, the population aged 60 and above in China is projected to reach 310 million, accounting for a significant portion of the total population [29]. - The population aged 65 and above in China reached 220 million, accounting for 15.6% of the total population, with over 190 million elderly suffering from chronic diseases, driving demand for chronic disease management and home medical devices [31]. - The number of first registrations for Class III medical devices in China reached 2,655, a year-on-year increase of 27.7%, indicating accelerated product iteration and growth in the industry [33]. - The number of online medical device sales companies in China increased from 8,700 in 2018 to 331,000 in 2024, highlighting the rapid growth of e-commerce as a sales channel for home medical devices [36]. Product Development and Innovation - The company has launched several high-quality best-selling products, including ventilators, oxygen machines, nebulizers, and smart electric wheelchairs, demonstrating a rich pipeline of R&D [51]. - The company has established a comprehensive product system covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy [53]. - The company has added 70 new authorized patents during the reporting period, bringing the total to 592 patents and 170 copyrights [63]. - The company launched over 100 new products during the reporting period, including a dual blood glucose and uric acid test strip that provides results in 10 seconds [60]. - The company has introduced a portable ventilator and a new generation sleep ventilator, enhancing its product line in respiratory support [84]. - The company has launched new products across various categories, including 1 completed trial production of a pure tone audiometer and 8 mass-produced smart in-ear hearing aids, enhancing product diversity and customer experience [85]. Research and Development - The company invested a total of 339 million yuan in R&D over the past three years, ranking 32nd in the 2024 China Medical Device R&D Comprehensive Strength Ranking [59]. - R&D investment amounted to approximately ¥106.66 million in 2024, representing 3.58% of operating revenue, down from 4.01% in 2023 [86]. - The company is committed to increasing R&D investment to enhance product performance and market responsiveness amid intense industry competition [129]. - The company aims to enhance its R&D capabilities and market share, continuing to focus on product innovation and brand development [41]. Marketing and Sales Strategy - The company has established a comprehensive marketing network with over 800 self-operated stores and partnerships with more than 200,000 pharmacies nationwide, enhancing its market presence [40]. - The company has developed a multi-channel sales strategy in China, integrating e-commerce platforms, chain pharmacies, and self-operated stores to enhance market reach [49]. - The company is focusing on online marketing strategies, targeting a 30% increase in online sales channels by the end of 2024 [135]. - The sales strategy includes leveraging digital tools for channel optimization, enhancing online sales through data analysis, and improving customer retention and repurchase rates [126]. Corporate Governance and Compliance - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring transparency and compliance with regulations [143]. - The company strictly follows information disclosure regulations, ensuring timely and accurate communication with shareholders through designated channels [144]. - The company maintains independence from its controlling shareholder in terms of personnel, assets, finance, and operations, with no violations reported [146]. - The company has established a comprehensive governance structure and strictly adheres to relevant laws and regulations to ensure sustainable development [196]. Social Responsibility and Community Engagement - The company has made significant investments in social responsibility, donating medical supplies to rural areas and elderly care centers, which enhances brand value [70]. - The company contributes to local economic growth by creating job opportunities and providing efficient healthcare solutions [200]. - The company is committed to balancing the interests of shareholders, employees, and society while focusing on environmental protection and corporate social responsibility [145]. Employee Management and Development - The total number of employees at the end of the reporting period was 5,099, with 1,146 in the parent company and 3,953 in major subsidiaries [171]. - The company has established a multi-dimensional assessment mechanism for salary management, integrating short-term rewards with long-term incentives [173]. - The company launched the "Spark Program" training series to enhance the professional capabilities and market insights of category managers [174]. - The company aims to create a healthy corporate culture by providing various employee benefits and facilities [173]. Future Outlook and Strategic Goals - The company plans to increase R&D efforts, focusing on differentiated, high-quality medical devices, and integrating AI with home medical devices for improved health monitoring solutions [122]. - The company aims to enhance its product portfolio with innovative medical devices to address various health conditions [88]. - The company is exploring potential mergers and acquisitions to enhance market share, with a focus on companies in the medical device sector [134]. - The company has set a revenue guidance of $500 million for the upcoming fiscal year, representing a 25% increase compared to the previous year [135].

Financial Performance - The company's revenue for Q1 2025 was ¥737,792,254.37, a decrease of 8.59% compared to ¥807,154,893.30 in the same period last year[5] - Net profit attributable to shareholders was ¥91,425,130.39, down 9.68% from ¥101,221,564.63 year-on-year[5] - Basic earnings per share were ¥0.45, a decline of 10.00% from ¥0.50 in the same period last year[5] - Net profit for the period was ¥91,572,859.16, down from ¥101,039,013.17, reflecting a decrease of approximately 9.5% year-over-year[22] - Total operating revenue decreased to ¥737,792,254.37 from ¥807,154,893.30, representing a decline of approximately 8.6% year-over-year[21] - Total operating costs decreased to ¥646,327,861.69 from ¥676,812,278.56, a reduction of about 4.5% year-over-year[21] Cash Flow - The net cash flow from operating activities decreased by 51.82%, amounting to ¥110,058,277.19 compared to ¥228,412,107.91 in the previous year[5] - Operating cash inflow for the current period was $791,876,819.30, a decrease of 5.6% from $838,733,918.37 in the previous period[25] - Total cash outflow from operating activities was $681,818,542.11, an increase of 11.7% from $610,321,810.46 in the previous period[25] - Cash received from sales of goods and services was $748,166,889.53, down from $809,679,385.05, indicating a decline of 7.6%[25] - Cash received from tax refunds increased to $2,065,452.90, up from $1,217,481.61, representing a growth of 69.9%[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,418,333,542.84, a slight decrease of 0.07% from ¥6,422,666,712.07 at the end of the previous year[5] - The company's total current assets amount to 3,913,564,439.07 RMB, slightly decreasing from 3,925,489,622.21 RMB at the beginning of the period[17] - Total liabilities decreased to ¥1,509,617,533.83 from ¥1,620,317,541.89, a reduction of approximately 6.8% year-over-year[19] - The total non-current assets are valued at 1,894,000,000 RMB, with fixed assets accounting for 1,480,634,778.64 RMB[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,428, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Changsha Medical Investment Co., Ltd., holds 40.69% of shares, amounting to 85,079,923 shares, with 8,010,000 shares pledged[13] - The top ten shareholders collectively hold a significant portion of the company's equity, with the top three shareholders alone accounting for over 50%[13] - The company has not reported any changes in the shareholding structure of the top ten shareholders due to margin trading activities[14] Investment and Expenses - The company reported a significant increase in investment income, which rose by 2492.20% to ¥10,327,107.82 from a loss of ¥431,699.64 in the previous year[10] - Management expenses increased by 37.52% to ¥40,596,125.82, primarily due to higher costs associated with the acquisition of a company[10] - Research and development expenses were ¥18,836,066.75, down from ¥22,369,153.88, indicating a decrease of about 15.5% year-over-year[21] - The company experienced a 33.90% increase in net cash outflow from investing activities, totaling -¥94,905,406.71, attributed to increased purchases of financial products[12] Equity and Minority Interests - The company’s total equity attributable to shareholders increased by 2.02% to ¥4,893,677,663.77 from ¥4,796,596,352.25 at the end of the previous year[5] - The company reported a 161.41% increase in minority interests, reaching ¥15,038,345.24, primarily due to the acquisition of a company[9] - The equity attributable to shareholders of the parent company increased to ¥4,893,677,663.77 from ¥4,796,596,352.25, an increase of about 2.0% year-over-year[19]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-021 可孚医疗科技股份有限公司 关于2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 可孚医疗科技股份有限公司（以下简称"公司"）拟以现有总股本 209,092,000 股剔除回购专用证券账户中已回购股份5,699,731股后的股本203,392,269股为基 数，向全体股东每 10 股派发现金分红 12 元（含税）。本次利润分配不送红股， 不以资本公积金转增股本。 一、审议程序 公司于 2025 年 4 月 25 日召开的第二届董事会第十四次会议和第二届监事会 第十四次会议审议通过了《关于公司 2024 年度利润分配预案的议案》。本次利 润分配预案尚需提交公司股东大会审议。 二、利润分配预案的基本情况 1. 本次利润分配预案为 2024 年度利润分配。 2. 根据《公司法》和《公司章程》规定，公司不存在需要弥补亏损、提取 法定公积金、提取任意公积金的情况。 经立信会计师事务所（特殊普通合伙）审计，2024 年度公司合并报表实现 归属于上市公司股东的净利 ...

可孚医疗科技股份有限公司 关于回购注销部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）于2025年4月25日召开的 第二届董事会第十四次会议和第二届监事会第十四次会议审议通过了《关于回购 注销部分限制性股票的议案》，根据公司《2021年限制性股票激励计划（草案）》 （以下简称"《激励计划》"）的规定和公司2021年第二次临时股东大会的授权， 董事会同意回购注销第三个解除限售期对应的19.50万股第一类限制性股票。现 将有关事项说明如下： 一、2021年限制性股票激励计划已履行的相关审批程序 1. 2021年12月5日，公司召开第一届董事会第十八次会议，会议审议通过了 《关于公司〈2021年限制性股票激励计划（草案）〉及其摘要的议案》《关于公 司〈2021年限制性股票激励计划实施考核管理办法〉的议案》以及《关于提请股 东大会授权董事会办理2021年限制性股票激励计划相关事宜的议案》，公司独立 董事对此发表了同意的独立意见，律师事务所等中介机构出具相应报告。 证券代码：301087 证券简称：可孚医 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）于2025年4月25日召开的 第二届董事会第十四次会议和第二届监事会第十四次会议审议通过了《关于作废 部分限制性股票的议案》，根据公司《2021年限制性股票激励计划（草案）》《2024 年限制性股票激励计划（草案）》的规定和公司2021年第二次临时股东大会及2024 年第一次临时股东大会的授权，董事会同意作废2021年限制性股票激励计划中 99.45万股第二类限制性股票，作废2024年限制性股票激励计划中20.50万股第二 类限制性股票。现将有关事项说明如下： 一、激励计划已履行的相关审批程序 （一）2021年限制性股票激励计划已履行的相关审批程序 证券代码：301087 证券简称：可孚医疗 公告编号：2025-026 可孚医疗科技股份有限公司 关于作废部分限制性股票的公告 1. 2021年12月5日，公司召开第一届董事会第十八次会议，会议审议通过了 《关于公司〈2021年限制性股票激励计划（草案）〉及其摘要的议案》《关于公 司〈2021年限制性股票激励计划实施考核管理 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-028 可孚医疗科技股份有限公司 关于2024年限制性股票激励计划首次授予部分第一个归属期 归属条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1. 本次符合归属条件的激励对象人数共计：308 人。 2. 本次拟归属数量：183.84 万股，占可孚医疗科技股份有限公司（以下简称 "公司"）目前总股本的 0.88%。 3. 本次归属条件成就之日为 2025 年 4 月 28 日。 4. 根据公司 2024 年限制性股票激励计划（以下简称"激励计划"）所有激 励对象承诺，自每个归属条件达成之日起 6 个月内，其所持有的当批次归属的全 部限制性股票不得转让。因此公司申请本次归属的限制性股票继续限售至 2025 年 10 月 27 日。公司将延迟到限售期结束时向深圳证券交易所、中国证券登记结 算有限责任公司深圳分公司申请办理本次归属股票的股份归属手续。届时公司将 另行公告，敬请投资者注意。 公司于 2025 年 4 月 25 日召开第二届董事会第十四次会议、第二届监事会第 ...

西部证券股份有限公司 关于可孚医疗科技股份有限公司 首次公开发行股票并在创业板上市 之保荐总结报告书 西部证券股份有限公司（以下简称"保荐人"或"西部证券"）作为可孚医疗科 技股份有限公司（以下简称"公司"或"可孚医疗"）首次公开发行股票的保荐人， 履行持续督导职责期限至 2024 年 12 月 31 日。目前，可孚医疗首次公开发行股票持 续督导期已届满，西部证券根据《证券发行上市保荐业务管理办法》《深圳证券交易 所上市公司自律监管指引第 13 号—保荐业务》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所创业板上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法规、规范性文件相关要求，出具本保荐总结报告书。 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导性陈 述或重大遗漏，保荐人及保荐代表人对其真实性、准确性、完整性承担法律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监会"） 对保荐总结报告书相关事项进行的任何质询和调查。 | 保荐人名称 | 西部证券股份有限公司 | | --- | --- | | 注册地址 | 陕西省西安市新城区东新街 号 ...

关于可孚医疗科技股份有限公司 2025 年度日常关联交易预计的核查意见 西部证券股份有限公司（以下简称"保荐人"）作为可孚医疗科技股份有限 公司（以下简称"可孚医疗"或"公司"）首次公开发行股票并在创业板上市的 保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等有关规定，对可孚医疗 2025 年度日常关联交易预计情况进行了核 查，核查情况如下： 一、日常关联交易基本情况 西部证券股份有限公司 （一）日常关联交易概述 1、根据公司业务发展及日常经营的需要，公司预计 2025 年度将与关联方湖 南楮墨仓科技有限公司（以下简称"楮墨仓"）发生日常关联交易不超过 240 万元。公司 2024 年度预计的关联交易额度为 350 万元，与预计关联方之间实际 发生的日常关联交易总金额为 163.32 万元。 2、公司于 2025 年 4 月 25 日召开的第二届董事会第十四次会议、第二届监 事会第十四次会议审议通过了《关于 2025 年度日常关联交易预计的议案》，关 联董事张敏先生已回避表决。该事项已经公司独立董事 ...